亦諾微醫藥遞交來港上市申請
專注於臨牀需求導向的未盈利生物科技公司亦諾微醫藥(Immvira Bioscience)今日循《上市規則》第18A章遞交來港上市申請,花旗及中金(3908)為聯席保薦人。
Last Update:
16 7 月, 2026
Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.